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ABSTRACT
The Pancreatic Expression database (PED, http://
www.pancreasexpression.org) has established
itself as the main repository for pancreatic-derived
-omics data. For the past 3 years, its data content
and access have increased substantially. Here we
describe several of its new and improved features,
such as data content, which now includes over
60 000 measurements derived from transcriptomics,
proteomics, genomics and miRNA profiles from
various pancreas-centred reports on a broad range
of specimen and experimental types. We also illus-
trate the capabilities of its interface, which allows
integrative queries that can combine PED data
with a growing number of biological resources
such as NCBI, Ensembl, UniProt and Reactome.
Thus, PED is capable of retrieving and integrating
different types of -omics, annotations and clinical
data. We also focus on the importance of data
sharing and interoperability in the cancer field, and
the integration of PED into the International Cancer
Genome Consortium (ICGC) data portal.
INTRODUCTION
Pancreatic cancer is the fourth leading cause of
cancer-related death world-wide (1) with surgical interven-
tion and radiotherapy having a minimal impact on 5-year
survival rates. As a result, patient survival rates have
remained relatively unchanged over the past 30 years.
Because of the poor prognosis associated with pancreatic
cancer, a multitude of studies have been dedicated to
elucidating the pathogenesis of this malignancy (2).
Augmented by advances in high-throughput technologies,
this has resulted in a plethora of -omics data. Despite the
magnitude of information available, the heterogeneity and
isolation of public datasets prevents researchers from
effectively mining, extracting and integrating relevant
data into their current research.
The publicly available Pancreatic Expression database
(PED) was developed to overcome these obstacles by
enabling complex pancreatic datasets to be manipulated,
mined and integrated with ease (3). Since its inception in
2007, PED has undergone extensive improvements. The
range of clinical and -omics data types available for
queries has broadened substantially, facilitating the sys-
tematic study of pancreatic cancer.
Unlike many cancer databases specialised in providing
single-type information, PED stores four different kinds
of -omics data: transcriptomics, proteomics, miRNA and
genomics. These proﬁles are derived from a broad range of
specimens from tissues and body ﬂuids of healthy people
or patients, cell lines and mouse models as well as different
treatments and drugs. This is key to providing a compre-
hensive overview of the molecular changes in cancer.
Another important feature of PED is that it allows for
its data to be interrogated from major gene repositories
such as NCBI EntrezGene (4) and Ensembl GeneView (5),
third-party software such as R statistical environment (6)
and Cytoscape (7) or jointly with data from major
biological resources such as the Reactome Pathway
project (8), PRIDE (9) and UniProt (10). Increased func-
tionality also allows for greater interoperability with inter-
national cancer efforts, such as the International Cancer
Genome Consortium (ICGC, http://www.icgc.org), a
major international collaboration designed to identify
the key genetic mutations involved in up to 50 types of
cancer, which will enable the development of new and
better ways of diagnosing, treating and preventing
cancer (11).
To the best of our knowledge, there are neither tools
nor databases that provide the same information
for cancer research as our platform. By allowing for inte-
gration and mining of published pancreatic cancer
data in the context of a wide range of annotations, PED
offers more options than raw data repositories such as
*To whom correspondence should be addressed. Tel: +44 20 7014 0474; Fax: +44 20 7014 0431; Email: c.chelala@qmul.ac.uk
Published online 18 October 2010 Nucleic Acids Research, 2011, Vol. 39, Database issue D1023–D1028
doi:10.1093/nar/gkq937
 The Author(s) 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. Integrated view of genomic and transcriptomic changes in pancreatic cancer. This ﬁgure integrates the results from both genome-wide
DNA copy number and genome-wide gene expression proﬁling. In a few seconds, this allows for visual inspection of copy number-driven expression
changes. Here the query is to ﬁnd genes differentially up-regulated in PDAC versus normal using microdissected ductal cells (A) and then combine
this information with data on genes that are also associated with genomic variations in PDAC samples by combining with results for copy number
changes on high level ampliﬁcations (B). Pick attributes for display (C). A summary of the ﬁrst 20 results is shown in (D).
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Gene Expression Omnibus (GEO) (12) or ArrayExpress
(13). One of the main strengths of our system is the
possibility of setting many ﬁlters to ask very speciﬁc
pancreatic cancer-related questions and obtain a focused
annotated data output. Here we outline details of the
improved data content, query interfaces and
interoperability.
IMPROVED DATA CONTENT
The database contains 56 015 differential or expression
measurements and 6363 DNA copy number alterations.
These data values are extracted from over 59 published
studies and include proﬁles from a large number of
specimen types, such as pancreatic tissues and various
body ﬂuids obtained from healthy subjects and patients
with benign, pre-malignant and malignant diseases. In
addition, studies using pancreatic cancer cell lines and
murine models have also been incorporated
(Supplementary Table S1). Where applicable, information
on the different treatment conditions applied is provided
to users.
The collected samples were proﬁled on a wide range
of transcriptomics, proteomics, miRNAs and gen-
omics platforms (Supplementary Table S2). To date,
PED describes pancreatic-related regulation events in
8229 genes/proteins, 27 327 transcripts and 279 miRNA
as well as 2771 gains, 1073 losses, 347 homozygous
deletions, 1297 high-level ampliﬁcations and 875 loss
of heterozygosity events occurring in distinct genomic
areas.
The data collection pipeline from the original data-
base was enhanced to cover not only transcriptomics
but also genomics, proteomics and miRNA information.
Data from the primary literature were manually curated,
reviewed for accuracy and consistency, and loaded
into a relational database. The Ensembl annotations
originally used for mapping probe identiﬁers and gene
names to standard values (version 48) have been
updated to a more current version (version 56). This
ensures that our database remains up-to-date with
ongoing improvements to annotation and microarray
probe set mappings and helps avoid data integrity
errors. The data collection process was expanded to en-
compass new data types such as DNA copy number
changes. Here, chromosomal coordinates for each copy
number variation identiﬁed from papers were mapped to
genome release GRCh37 with conversions between
genome versions carried out using the liftover tool from
UCSC (14).
We imported the available Ensembl human gene anno-
tations (5) for genes, proteins, SNP information, se-
quences, gene structure and multi-species data, enabling
the integration and annotation of heterogeneous pancre-
atic data (Supplementary Table S3).
Figure 2. Cross-linking pathways information from reactome. Results from the previous query (shown in Figure 1) can be further mined and merged
with data from Reactome. Here we select Reactome pathways as a second dataset to combine in queries and then restrict obtained information to
‘Homo sapiens’ data (A). Pick attributes and display a summary of the ﬁrst 20 results (B). Query results return pathway name and stable ID with a
hyper-link to the Reactome website allowing to instantly extract data (C).
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IMPROVED QUERY CAPABILITIES
While the original PED system included tools for querying
across different tumour stages of pancreatic cancer and
different pancreatic disease types in a simple integrated
way (3), the interface has been greatly improved to
provide the user access to the expanded data content. By
including new platforms, comparisons and data types, it is
possible to combine information and, therefore, to
perform more complex queries than by viewing expression
data alone. For example, it is possible to highlight the
impact of copy number aberrations on gene expression
patterns to ﬁlter out genes whose expression levels are
not consistent with their DNA copy number status and
point to the subset of candidate oncogenes or tumour sup-
pressor genes showing copy number-driven expression
changes (Figure 1). There are now options available for
proteomics, transcriptomics and miRNA proﬁling,
allowing these data types to be queried in isolation or
combined to look for genes consistently identiﬁed across
different data technologies or to extract speciﬁc data such
as microRNAs deregulated in the different stages of pan-
creatic cancer.
The new interface incorporates the full functionality
and data from Ensembl Mart 56 including richer data
content and more advanced querying capabilities and
also makes better use of the BioMart interface capabilities
(15) for cross-linking different datasets that have data
types in common; for example by combining PED data
with Reactome pathway data of human reactions and
pathways (8) (Figure 2). This integration allows research-
ers to quickly identify both pancreatic cancer genes and
the pathways they control.
IMPROVED DATA ACCESS
PED is freely accessible through a BioMart web-
based query interface at http://www.pancreasexpression
.org. PED is also a DAS server (16) providing DAS
annotations for the wider community, so it can be
used in other resources or browsers such as Ensembl
GeneView using the GeneDAS protocol. Access is also
possible via web services through third party software
tools that have been made compatible with BioMart
resources such as Bioconductor (http://www.
bioconductor.org) (6,17), Galaxy (18) and Cytoscape (7).
Interoperability with the ICGC is also possible through
this web services layer and PED is now available
through the ICGC data portal (http://dcc.icgc.org)
(Figure 3) allowing researchers to conduct combined
queries on ICGC experimental data alongside PED litera-
ture data. This further increases the ways in which the
database can be accessed and its exposure to a variety of
disciplines and interests in the scientiﬁc community. The
database is also accessible as a Linkout resource from
NCBI EntrezGene (4). This allows EntrezGene users
to be alerted to pancreatic expression data by the
presence of a data link for relevant genes that are in the
database.
DISCUSSION
We have described how PED has evolved from its original
role as a repository for cancer transcriptomics data into a
comprehensive resource capable of providing a quick
overview of molecular changes at the transcriptome,
proteome, genome and/or miRNA level. Consequently,
there has been a huge growth in its -omics, specimen/
clinical and annotation data content.
We believe that interoperability is a key factor in the
utility and productive use of any current and future cancer
databases. This is essential to ensure the sustainability of
any cancer database and facilitate its integration with
major international efforts in cancer research such as the
ICGC. This will also allow the design and implementation
of more sophisticated analysis portals. The cancer
research community needs open source, fully interoper-
able resources allowing information connectivity and
data sharing. Only these types of resource can ensure
that cancer data generated across different organisations
are shared, thereby maximising the impact of cancer
research. By using the BioMart technology for its data
management system, PED is fully interoperable with the
ICGC. This ensures that PED is integrated with The
Cancer Genome Atlas (TCGA, http://cgap.nci.nih.gov)
data available through the ICGC data portal. The
BioMart web service layer also allows PED to be
integrated with several other data sources that also use
the BioMart technology such as Reactome, PRIDE,
UniProt and Ensembl. Moreover, PED is a Linkout
resource integrated with NCBI.
Our database ﬁlls the urgent requirement of the pancre-
atic cancer community for resources capable of integrating
the overﬂowing inﬂux of data generated by novel
high-throughput technologies.
The architectural ﬂexibility of PED is easily extendable
to other disease types, with this model being used to create
a similar resource for malignant (breast cancer) and
non-malignant (neurodegenerative) diseases. Reuse of a
similar database design will facilitate complex query
capabilities across multiple diseases and data types.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Figure 3. Interoperability with the ICGC experimental data. Access available from http://dcc.icgc.org. The ﬁgure shows the ICGC data portal report
for the TP53 gene including gene information; ICGC experimental sequencing results obtained from the participating centres; and PED data. In the
PED Report section, a heatmap represents, visually, the level of de-regulation as extracted from the original publication and stored in PED. If you
hold your mouse over the coloured box, it will display the fold change value (when available).
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